[Risk of thrombosis in XXXX . A review with new results of studies].

@entity1 @entity11271 @entity5 @entity73 @entity2622 @entity189 @entity49 @entity4770 @entity1031
Malignomas of the uterus predispose to @entity1031 . Local application of radium increases the activation of hemostasis. In newer examinations there are hints, that @entity73 and @entity4770 metabolism may have a pathogenetic meaning. Thrombocyte aggregation and @entity4770 sensitivity of thrombocytes have been examined in two groups of @entity1 : 21 @entity1 following hysterectomy because of @entity5 stage I, treated with one vaginal application for the vaginal cuff and 10 @entity1 with @entity2622 Stage IIa-IIIb treated combined intrauterine-intravaginally. The first group was prophylactically treated with low-dose-heparin, the second one with @entity11271 (Sintrom). A slight, but significant increase of thrombocyte aggregation by 4.8 per cent respectively 5.0 per cent could be observed in both groups. @entity4770 sensitivity of thrombocytes (PST) was significantly reduced by 20 per cent before irradiation in all @entity1 compared with @entity1 without @entity189 . In cases of intravaginal radium application we saw immediately after removal of the radioactive source a further reduction of PST by 12.5 per cent. 24 hours later a significant decrease of PST by 18.5 per cent could be observed. Contrary to this no significant changes were induced by combined intrauterine and intravaginal radium insertion. Therefore reduction of PST may be interpreted as a possible change of thrombocyte function in vivo caused by irradiation. It may be likely that these disturbances of thrombocyte function combined with radiogenic vessel wall damages and @entity49 are responsible for the high thromboembolic risk of radium therapy. These @entity1 should be treated prophylactically. Probably the efficiency of this prophylaxis can be improved by additional application of selective inhibitors of thrombocyte aggregation or inductors of @entity4770 synthesis.
